Abstract
The microbial community of the gut, collectively termed the gut microbiota, modulates both host metabolism and disease development in a variety of clinical contexts. The microbiota can have detrimental effects and be involved in disease development and progression, but it can also offer benefits to the host. This has led in the last years to the development of different therapeutic strategies targeting the microbiota. In this review, we will focus on one of these strategies that involve the use of engineered bacteria to modulate gut microbiota in the treatment of metabolic disorders. We will discuss the recent developments and challenges in the use of these bacterial strains with an emphasis on their use for the treatment of metabolic diseases.
Original language | English |
---|---|
Article number | e14001 |
Number of pages | 14 |
Journal | Acta Physiologica |
Volume | 238 |
Issue number | 3 |
Early online date | 24 May 2023 |
DOIs | |
State | Published - Jul 2023 |
All Science Journal Classification (ASJC) codes
- Physiology